Lilly Endowment, Inc., an Indiana not‑for‑profit private foundation, reported its ownership of 92,190,516 shares of Eli Lilly and Company common stock as of December 31, 2025. This stake represents 9.8% of Eli Lilly’s outstanding common stock, based on 945,383,757 shares outstanding as of October 27, 2025, as referenced from Eli Lilly’s Form 10‑Q for the period ended September 30, 2025.
The endowment has sole voting power and sole dispositive power over all 92,190,516 shares and reports no shared voting or shared dispositive power. None of these shares are reported as being beneficially owned through rights to acquire additional shares; they reflect existing common shares held by the endowment.
Eli Lilly and Company director Gabrielle Sulzberger reported a small acquisition of company stock as part of board compensation. On January 20, 2026, she acquired 4.762 shares of Eli Lilly common stock at a price of $1,041.29 per share, bringing her directly held beneficial ownership to 2,961.436 shares.
According to the filing, these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They are credited as stock units and are scheduled to be settled in actual shares of common stock after her separation from service as a director. The transaction reflects routine director compensation rather than an open-market purchase or sale.
Eli Lilly and Company director Juan R. Luciano reported an acquisition of company common stock through the deferral of board compensation. On January 20, 2026, he acquired 15.286 shares of Eli Lilly common stock at a price of $1,041.29 per share, recorded as an "A" transaction. After this transaction, he beneficially owned 16,756.656 shares of Eli Lilly common stock in direct ownership.
According to the disclosure, Mr. Luciano elected to defer his cash compensation into stock units under the Lilly Directors' Deferral Plan. These deferred stock units will be settled in shares of common stock after he separates from service as a director, meaning the award is part of his director compensation structure rather than an open-market purchase.
Eli Lilly & Co. director J. Erik Fyrwald reported an acquisition of company common stock through a compensation deferral arrangement. On January 20, 2026, he acquired 9.523 shares of Eli Lilly common stock at $1,041.29 per share, increasing his directly held beneficial ownership to 75,110.75 shares.
According to the disclosure, these shares were not received as immediate cash pay but were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They will be settled in shares of common stock after Fyrwald separates from service as a director, reflecting standard equity-based director compensation rather than an open-market trade.
Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.924 shares of Eli Lilly common stock on January 20, 2026. According to the filing, this amount represents fees that he elected to defer as stock units under the Lilly Directors' Deferral Plan, instead of taking cash, and these units will be settled in Eli Lilly common shares after he leaves board service.
Following this transaction, Alvarez directly beneficially owned 55,479.642 shares of Eli Lilly common stock. The filing also reports an additional 758 shares held indirectly through a trust, for which he disclaims beneficial ownership except to the extent of his economic interest.
Eli Lilly & Co filed an initial ownership report showing a significant equity position in Aktis Oncology, Inc. (AKTS). As of 01/12/2026, Eli Lilly beneficially owned 6,344,114 shares of Aktis Oncology common stock, reported as a direct holding and establishing it as a 10% owner of the company. The filing does not list any derivative securities, so the disclosed stake consists solely of common shares. This type of report is a standard regulatory disclosure of a large shareholder’s position.
Lilly Endowment Inc., a more than 10% owner of Eli Lilly and Company (LLY), reported a series of open-market sales of Eli Lilly common stock on January 7, 2026. The Form 4 shows multiple block sales at weighted average prices generally between $1,085.108 and $1,116.686 per share, with each price reflecting numerous individual trades within narrow ranges as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owned 91,896,978 shares of Eli Lilly common stock held directly.
Eli Lilly and Company executive Carole Ho, EVP & President of Lilly Neuroscience, reported her beneficial ownership of derivative equity awards. She holds restricted stock units covering 2,741.306 shares of Eli Lilly common stock. These RSUs vest in three installments: 904.631 units on December 1, 2026, 932.044 units on December 1, 2027, and 904.631 units on December 1, 2028. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly common stock, aligning a portion of her compensation with the company’s share performance over time.
Lilly Endowment Inc., a more than 10% owner of Eli Lilly & Co. (LLY), reported a sale of company stock. On 01/05/2026, the reporting person sold 1,390 shares of Eli Lilly common stock at a weighted average price of $1,085.011 per share. The sale was executed in multiple trades at prices ranging from $1,085.00 to $1,085.10.
Following this transaction, the reporting person beneficially owned 92,189,126 shares of Eli Lilly common stock in direct ownership. The filing notes that detailed trade-by-trade pricing information within the reported range will be provided upon request. The form was signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.
Eli Lilly & Co reported an insider transaction by a director-level reporting person. On 12/29/2025, the reporting person sold 3,593 shares of Eli Lilly common stock in an open-market transaction coded "S".
The weighted average sale price was $1,085.035 per share, with individual trades executed between $1,085.00 and $1,085.245. After this sale, the reporting person directly beneficially owned 92,190,516 Eli Lilly shares.